A Phase Ⅰ Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of QL1706H in Advanced Solid Tumors
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary) ; Iparomlimab/tuvonralimab (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Qilu Pharmaceutical
- 26 Sep 2023 New trial record